Early Retirement buyout
61% YOY gains.
CASH FLOW POSITIVE 2 quarters in a row.
6 straight quarters of double and triple digit gains YOY
No obligation to SunGen for GodZilla the $2.0 Billion CNS stinulant. CNS stimulant fully owned by Elite. ALL in on this one. $2 Billion IQVIA market
Elite doing All R&D in-house currently
Loxapine API imminent due any day from India
Loxapine on Drug Shortage List
Loxapine launch 1st quarter 2021
Loxapine $5 million IQVIA market with 4 competitors
Elite has a sales and marketing partner in place for Loxapine
Elite has competitive advantage on high entry barrier ER formulas
$2.484 million profit this quarter
Isradipine has upside potential
Elite streamlining using SAP technology
No obligation to SunGen for GodZilla the $1.5 Billion CNS stinulant.
Debt to market cap : 7%
“Elite is attractive for Merger or BuyOut”
Adderall IR and ER have strong UPSIDE POTENTIAL $2 billion combined market
New Equipment for production line - NEW 30 cubic foot V-blender
NEW higher speed tablet press. Facility upgrades.
One shift can do 300 million capsules a month.
Upgraded the Packaging Line - capacity increased by 25%
Back to school Adderall
Lannett Glenmark and Tagi continue to penetrate the markets
Walgreens Largest Customer 15% of market
$75 million tax credit, no taxes on first $75 million profit.
FDA reviewing $94 million SunGen Antibiotic ANDA waiting on response from FDA
Elite will reacquire full rights to Adderall IR and ER which Nasrat paid millions via Micah to protect these interests until Elite can take full control / ownership of them
Partnerships, merger, contract development, licensing opportunities, contract manufacturing, new ANDAs etc
Market Data 
Markets 
AI
